Gabapentin and tinnitus relief

International Tinnitus Journal

Volumn 14, Issue 1, 2008, Pages 1-5

  Shulman, Abraham ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLONAZEPAM; GABAPENTIN;

AUDIOLOGY; BLOOD BRAIN BARRIER; BRAIN FUNCTION; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; EDITORIAL; ELECTROENCEPHALOGRAPHY; HEARING; HUMAN; IDIOPATHIC DISEASE; NEUROPROTECTION; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TINNITUS;

AMINES; ANTICONVULSANTS; BRAIN; CLINICAL TRIALS AS TOPIC; CYCLOHEXANECARBOXYLIC ACIDS; GAMMA-AMINOBUTYRIC ACID; HUMANS; RECEPTORS, GABA-A; SELECTION BIAS; TINNITUS; TREATMENT OUTCOME;

EID: 46049102592     PISSN: 09465448     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (32)

1. Picirillo JF, Finnell J, Vlahiotis A, et al. Relief of idiopathic subjective tinnitus: Is gabapentin effective? Arch Otolaryngol Head Neck Surg 133:390-397, 2007.
2. A-benzo-diazepine- chloride receptor-targeted therapy for tinnitus control: Preliminary report. Int Tinnitus J 8(1):30-36, 2002.
3. Shulman A, Strashun AM, Afriyie M, et al. SPECT imaging of brain and tinnitus - neurotologic/neurologic implications. Int Tinnitus J 1(1):13-29, 1995.
4. Shulman A, Goldstein B. Quantitative electroencephalography: Preliminary report - tinnitus. Int Tinnitus J 8(2): 77-86, 2002.
5. Shulman A. Correspondence [JF Picirillo], November 30, 2004.
6. Shulman A. Medical-Audiologic Tinnitus Patient Protocol. In A Shulman. JM Aran, J Tonndorff, et al. (eds), Tinnitus Diagnosis/Treatment. Philadelphia: Lea & Febiger, 1991:319-321.
7. Shulman A. Clinical Types of Tinnitus. In A Shulman. JM Aran, J Tonndorff, et al. (eds), Tinnitus Diagnosis/Treatment. Philadelphia: Lea & Febiger, 1991:323-341.
8. Shulman A. Subjective Idiopathic Tinnitus - Clinical Types - A System of Nomenclature and Classification. In NH Feldmann (ed), Proceedings of the Third International Tinnitus Seminar, Munster, 1984. Karlsruhe: Harsch Verlag, 1999:136-141.
9. Shulman A, Seitz M. Central tinnitus diagnosis - treatment. Observations of simultaneous brainstem responses with monaural stimulation in the tinnitus patient. Laryngoscope 91:2025-2035, 1981.
10. Itard JMG. Die Krankheiten des Ohres und des Gehors. Weimar: 1822.
11. Vernon JA, Schleuning AJ. Tinnitus. A new management. Laryngoscope 85:413-419, 1978.
12. Hazell JWP, Hallam RS. Tinnitus masking - a significant contribution to tinnitus management. Br J Audiol 15:223-230, 1981.
13. Jastreboff PJ, Hazell JWP. A neurophysiological approach to tinnitus: Clinical implications. Br J Audiol 27:1-111, 1993.
14. Feldmann H. Homolateral and contralateral masking of tinnitus by noise bands and by pure tones. Audiology 10: 138-144, 1971.
15. Shulman A, Goldstein B. Subjective idiopathic tinnitus. A review of clinical experience, 1979-2005. Otolaryngol Minerva Med 55(1):1-11, 2005.
16. Shulman A. Tinnitology, tinnitogenesis, nuclear medicine, and tinnitus patients. Int Tinnitus J 4(2):102-108, 1998.
17. Lechtenberg R, Shulman A. Benzodiazepines in the treatment of tinnitus. J Laryngol Otol (Suppl) 9:272-277, 1984.
18. Shulman A, Strashun AM, Seibyl JP, et al. Benzodiazepine receptor deficiency and tinnitus. Int Tinnitus J 6(2):98-111, 2000.
19. Daftary A, Shulman A, Strashun AM, et al. Benzodiazepine receptor distribution in severe intractable tinnitus. Int Tinnitus J 10(1):17-23, 2004.
20. Farb DH, Borden LA, et al. Modulation of neuronal function through benzodiazepine receptors: Biochemical and electrophysiological studies of neurons in primary monolayer cell culture. Ann N Y Acad Sci 435:1-31, 1984.
21. Shulman A. Neuroprotective drug therapy: Medical and pharmacological treatment for tinnitus control. Int Tinnitus J 3(2):77-93, 1991.
22. Shulman A. Noise calpain, calpain inhibitors, and neuro protection: A preliminary report of tinnitus control. Int Tinnitus J 4(2):134-140, 1998.
23. Shulman A, Goldstein B. Pharmacotherapy for severe disabling subjective idiopathic tinnitus. Int Tinnitus J 12(2): 161-171, 2006.
24. Sills GI. Not another gabapentin mechanism. Epilepsy Curr 5(2):75, 2005.
25. Goa KL, Sorkin EM. Gabapentin: A review of its pharmacological properties and clinical potential in epilepsy. Drugs 46:409-427, 1993.
26. 2+ influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. Br J Pharmacol 130:900-906, 2000.
27. 2+ influx and synaptic transmission in rat hippocampus and neocortex. Eur J Pharmacol 449:221-228, 2002.
28. b heteroreceptors in rat cortical slices. Eur J Pharmacol 495:137-143, 2004.
29. B receptor agonist. Neuropharmacology 41:965-975, 2001.
30. Jensen AA, Mosbacher J, Elg S, et al. The anticonvulsant gabapentin (Neurontin) does not act through γ-aminobutyric acid-B receptors. Mol Pharmacol 61:1377-1384, 2002.
31. Bauer CA, Brozoski TJ. Effect of gabapentin on the sensation and impact of tinnitus. Laryngoscope 116(5):675-681, 2006.
32. Zapp JJ. Gabapentin for the treatment of tinnitus: A case report. Ear Nose Throat J 80:114-116, 2001.